Delayed Salivary Melatonin Onset Linked to ALS Progression
A new study reveals that later onset of salivary melatonin is associated with accelerated disease progression in ALS patients.
Later salivary melatonin onset correlates with faster ALS progression.
Study involved 50 ALS patients and assessed melatonin levels at home.
Findings suggest potential for melatonin as a prognostic biomarker in ALS.
A recent study has found that a delayed onset of salivary melatonin in patients with amyotrophic lateral sclerosis (ALS) is linked to quicker disease progression and poorer survival rates. The research highlights the significance of melatonin timing as a potential indicator of disease severity in ALS, particularly in its early stages.
The study involved a cohort of 50 ALS patients who were within 18 months of symptom onset. Participants underwent home-based salivary melatonin sampling under dim-light conditions at six specific time points around their usual sleep onset. This method allowed researchers to objectively measure the dim-light melatonin onset (DLMO), which serves as a marker for circadian phase timing. The results indicated that ALS patients exhibited an earlier DLMO compared to age- and sex-matched controls, despite having similar sleep onset times.
Statistical analysis revealed that a later baseline DLMO in ALS patients was associated with worse functional and motor status, as well as an increased likelihood of developing respiratory symptoms such as dyspnoea within six months. Specifically, the adjusted odds ratio indicated that patients with a later DLMO were over three times more likely to experience these adverse outcomes. The study also noted that DLMO levels remained stable over a six-month period in a subgroup of patients who were re-evaluated.
The implications of these findings are significant for the management of ALS, as they suggest that circadian rhythm disturbances may play a role in the disease's progression. While the study presents promising data regarding the prognostic potential of DLMO, researchers caution that further studies with larger independent cohorts are necessary to validate these findings. Currently, DLMO is considered an exploratory measure rather than a definitive clinical tool.
Looking ahead, the research opens avenues for future studies aimed at understanding the role of circadian rhythms in ALS and their potential use in clinical settings. As more data becomes available, there is hope that DLMO could eventually serve as a reliable prognostic biomarker, aiding in the early identification of patients at risk for rapid disease progression.
